Mobile

A study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 in people with HCV. "Experimental" means that they have not been approved by any regulatory agency ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-005740-95

A study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 in people with HCV. "Experimental" means that they have not been approved by any regulatory agency for sale to the public

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of this study are to evaluate the safety of 12 weeks of treatment with ABT-450/r/ABT-267 and ABT-333 with and without RBV, and to show the non-inferiority in SVR12 rates (the percentage of subjects achieving a 12-week sustained virologic response, SVR12, [HCV RNA < LLOQ 12 weeks following therapy]) of both arms to the historical SVR rate of telaprevir plus pegIFN and RBV.

Critère d'inclusion

  • Chronic Hepatitis C Infection

Liens